Exhibitor Map

AA Pharma is committed to consistently meeting Canadian regulatory, quality, and compliance requirements. Our strict adherence ensures we achieve the highest level of quality and consistency in our legacy pharmaceuticals and services so that we can continue to deliver the very best for Canadian patients.


The APA Foundation was created in 2008 to raise funds for education and research in the field of mental health. Your donations will help the APA Foundation bring noted speakers to present at future APA Conferences while still keeping registration fees low so as to encourage full industry participation and education


Fetzima is the only SNRI that offers a 2-fold greater selectivity for norepinephrine versus serotonin reuptake inhibition.  Fetzima is a unique SNRI that significantly improved patient motivation, energy and functioning.

Viibryd is a unique SSRI that offers efficacy in MDD with minimal effect on sexual function and weight.  Viibryd is both a selective serotonin reuptake inhibitor and a partial agonist of the 5HT1A receptors.


As one of Canada’s largest medical laboratory and health solutions companies, Dynacare cares for more than 10 million Canadians every year. We provide accurate and timely delivery of medical laboratory test results and other health-related services to hospitals, healthcare professionals, and Canadians through our personal health management portal called Dynacare Plus. Through Dynacare Genetics and Specialty Services, we are continually expanding our test menu as new procedures and markers of clinical utility are identified. We also provide genetic cancer testing and genetic prenatal testing for common fetal trisomies. Recently, we are pleased to add pharmacogenomic testing to our services. This helps shorten the path to effective treatment by studying the genetic factors that influence patients’ reactions to particular drugs, including Genecept, a pharmacogenetic test for mental health conditions.


CLOZARIL® along with the CLOZARIL® Support and Assistance Network (CSAN®) are uniquely effective for a patient population living with treatment-resistant schizophrenia, and has been striving to optimize outcomes since 1991.


Janssen Inc., a pharmaceutical company of Johnson & Johnson, has been an innovator in the Canadian healthcare industry for over 50 years.  We are guided by Our Credo, where our first responsibility is to the doctors, nurses and patients, and mothers and fathers, and all others who use our products and services. Our ultimate goal is to help people live healthy lives. Janssen’s history and our values provide the focus for our contributions to healthcare today and in the future. We have treatments within the divisions of Oncology, Immunology, Neurosciences, Infectious Diseases and Vaccines, Cardiovascular and Metabolic Diseases.


We know the brain.

Lundbeck is uncompromisingly committed to the research, development and delivery of targeted therapies for people living with significant psychiatric and neurological disorders. We believe life is too beautiful to be interrupted by brain disorders. So, we pursue imaginative solutions, driven by passionate people committed to do the right thing for our patients, our company and our communities. For Lundbeck, making a meaningful difference for those with lived experience is more than an aspiration: it is a commitment that shapes everything we do. Our advocacy is at the core of who we are and motivates every individual at Lundbeck. Our ongoing engagement with patient communities is not what you might expect from a pharmaceutical company - we work with organizations to help empower people. We believe in challenging the status quo, because Canadians living with brain disorders deserve better.


We specialize in building risk-managed, tax-efficient strategies for clients with sophisticated financial needs and dedicate ourselves to a niche group of clients to ensure the highest level of service possible.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.ca. We routinely post information that may be important to investors on our website at investor.mylan.com.


Otsuka-people creating new products for better health worldwide

Otsuka Canada Pharmaceutical Inc. (OCPI) is an innovative, fast-growing health care company that commercializes Otsuka medicines in Canada, with a focus on commitment to neuroscience, cardiovascular, and oncology. OCPI is dedicated to improving patients' health and the quality of human life. OCPI is part of the Otsuka Group, and was established in 2010, with headquarters in Technoparc Montreal, in Saint-Laurent, Quebec.


The Physician and Family Support Program (PFSP)- a voluntary program that provides confidential support and help with personal health issues. Part of the AMA’s physician benefits program, PFSP enhances the quality of patient care and public safety by supporting the health and well-being of the medical profession that cares for all Albertans.


Purdue Pharma (Canada) is a research-based pharmaceutical and consumer healthcare company which has operated in Canada for over 60 years.  Its 400 employees are committed to improving the health and quality of life of Canadians. The company has a broad portfolio of prescription and non-prescription medications including: prescription treatments for pain, ADHD, chemotherapy-induced nausea and vomiting (CINV), various ophthalmic conditions and Consumer Healthcare products.  The company supports evidence-based education for the safe use of its products. Its headquarters, located in Pickering, ON, include integrated research & development, formulation and manufacturing operations.  Privately held and founded by physicians, Purdue Pharma (Canada) is independently associated with the worldwide Purdue/Napp/Mundipharma network of companies.


Shire is strongly driven by a desire to enable Canadians lead better lives and to contribute positively to the health of the communities where we live and operate. As a leader in ADHD education and treatment, Shire’s first obligation is to people who have been appropriately diagnosed with ADHD by a healthcare professional. ADHD is a neurobiological disorder that requires professional management in order for patients to reach their full potential.


Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. The Company has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological, and respiratory conditions.